| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Chengdu Kanghua Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥51.97 |
| 52 Week High | CN¥84.05 |
| 52 Week Low | CN¥44.78 |
| Beta | 2.42 |
| 11 Month Change | -2.15% |
| 3 Month Change | -10.24% |
| 1 Year Change | -12.82% |
| 33 Year Change | -56.29% |
| 5 Year Change | n/a |
| Change since IPO | 15.40% |
Recent News & Updates
Shareholder Returns
| 300841 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 5.5% | 2.3% | 1.5% |
| 1Y | -12.8% | -22.6% | -18.8% |
Return vs Industry: 300841 exceeded the CN Biotechs industry which returned -23.5% over the past year.
Return vs Market: 300841 matched the CN Market which returned -13.4% over the past year.
Price Volatility
| 300841 volatility | |
|---|---|
| 300841 Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 300841 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300841's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 700 | Hongbo Wu | www.kangh.com |
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines.
Chengdu Kanghua Biological Products Co., Ltd. Fundamentals Summary
| 300841 fundamental statistics | |
|---|---|
| Market cap | CN¥6.82b |
| Earnings (TTM) | CN¥567.57m |
| Revenue (TTM) | CN¥1.68b |
12.0x
P/E Ratio4.0x
P/S RatioIs 300841 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300841 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.68b |
| Cost of Revenue | CN¥102.51m |
| Gross Profit | CN¥1.58b |
| Other Expenses | CN¥1.01b |
| Earnings | CN¥567.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.33 |
| Gross Margin | 93.91% |
| Net Profit Margin | 33.70% |
| Debt/Equity Ratio | 5.1% |
How did 300841 perform over the long term?
See historical performance and comparison